What is Cleerly?
Cleerly is at the forefront of revolutionizing cardiovascular diagnostics. The company leverages advanced machine intelligence to analyze non-invasive CT imaging, providing a comprehensive understanding of coronary artery disease. By enhancing health literacy for all stakeholders in the cardiac care pathway, Cleerly aims to shift the paradigm towards value-based precision diagnostics. Headquartered in New York City, the company is driven by a distinguished team of clinical and technical experts dedicated to improving patient outcomes and streamlining the diagnostic process.
How much funding has Cleerly raised?
Cleerly has raised a total of $386.6M across 5 funding rounds:
Series A
$14.5M
Debt
$150K
Series B
$43M
Series C
$223M
Other Financing Round
$106M
Series A (2017): $14.5M, investors not publicly disclosed
Debt (2020): $150K led by PPP
Series B (2021): $43M supported by New Leaf Venture Partners, DigiTx Partners, Vensana Capital Management, and LRVHealth
Series C (2022): $223M featuring Piper Heartland Healthcare Capital, Fidelity Management and Research Company, Merchant Banking, T. Rowe Price Associates, Sands Capital, and T. Rowe Price Investment Management
Other Financing Round (2024): $106M backed by Insight Partners and Battery
Key Investors in Cleerly
Insight Partners
Insight Partners is a global venture capital and private equity firm that invests in high-growth software and technology companies. They provide capital and operational support to help businesses scale from early stage to IPO, focusing on enterprise software, SaaS, and internet platforms.
Battery
Battery Ventures is a global investment firm that partners with entrepreneurs and management teams to build and scale category-defining technology businesses. The firm focuses on identifying innovative companies across various stages of growth and supporting them with capital, strategic guidance, and industry expertise.
Sands Capital
Established in 1992, Sands Capital Management is headquartered in Arlington, Virginia. They manage equity mutual funds, invest in public equity markets, and more.
What's next for Cleerly?
With the recent injection of $106M and a cumulative funding of $386.7M, Cleerly is poised for significant expansion and further development of its diagnostic platform. This enterprise-level funding suggests a strategic focus on scaling operations, enhancing its machine intelligence capabilities, and broadening market penetration. The company's commitment to a value-based approach in heart disease diagnostics positions it to capture a larger share of the healthcare market, potentially leading to further strategic partnerships and technological advancements in the coming years.
See full Cleerly company page
